Study Comparing Synthetic Vascular Grafts in Patients With Peripheral Artery Disease (PAD) Who Require Artery Bypass. (FINEST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01113892
Recruitment Status : Completed
First Posted : April 30, 2010
Last Update Posted : January 16, 2014
Information provided by (Responsible Party):
Maquet Cardiovascular

Brief Summary:
To demonstrate the patency and safety of vascular grafts: EXXCEL and FUSION Bioline. The investigators expect the performance of the grafts to be similar.

Condition or disease Intervention/treatment Phase
Peripheral Arterial Occlusive Disease Device: vascular grafts Not Applicable

Detailed Description:
The study is a prospective, randomized, single-blind, two-arm, parallel group, multi-center study to evaluate the safety and efficacy of FUSION™ Vascular Graft with Bioline (heparin) coating, compared with EXXCEL Soft ePTFE in a peripheral bypass setting, to support a claim of substantial equivalence.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 207 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Comparison of Safety and Primary Patency Between FUSION Vascular Graft With Bioline and EXXCEL Soft ePTFE (FINEST)
Study Start Date : April 2010
Actual Primary Completion Date : December 2012
Actual Study Completion Date : October 2013

Arm Intervention/treatment
Active Comparator: EXXCEL Soft Device: vascular grafts
All devices will be used to treat patients with peripheral arterial occlusive disease

Experimental: FUSION Bioline Device: vascular grafts
All devices will be used to treat patients with peripheral arterial occlusive disease

Primary Outcome Measures :
  1. Primary Efficacy [ Time Frame: 6 months ]
    Primary Patency

Secondary Outcome Measures :
  1. Secondary Efficacy [ Time Frame: 6 months ]
    • Primary assisted patency
    • Secondary patency
    • Suture hole bleeding at the time of graft implantation procedure

  2. Safety [ Time Frame: Post-procedure, 30 days, 6 months, 12 months ]

    Safety endpoint is the composite of Major Adverse Limb Events and Periprocedural Deaths, including:

    • Major amputation
    • Major graft reintervention
    • Procedure-related death

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient requires either above-knee or below-knee femoral popliteal bypass;
  • Patient has Category 1, 2, 3 4 or 5 chronic limb ischemia as defined by the Rutherford Categories - chronic limb ischemia severity classification scale.
  • Patient is at least 21 years of age;
  • Patient has postoperative life expectancy of >18 months;
  • Patient is willing and able to provide written, informed consent.

Exclusion Criteria:

  • Patient has a previous history of bypass in the diseased extremity (below iliacs);
  • Patient had percutaneous transluminal angioplasty or stenting of the target femoral or popliteal artery at the anticipated site of the proximal or distal anastomosis within the previous 30 days;
  • Patient has active infection in the region of graft placement;
  • Patient has an acute arterial occlusion requiring an emergent intervention;
  • Patient requires sequential extremity revascularizations or other procedures that require use of additional vascular grafts;
  • Patient has known hypersensitivity or contraindication to aspirin;
  • Patient has known coagulation disorders including hypercoagulability;
  • Patient has previous instance of Heparin induced Thrombocytopenia type 2 or has known hypersensitivity to heparin;
  • Patient has severe chronic renal insufficiency, is undergoing hemodialysis. or has prior renal transplant;
  • Patient had a stroke or MI within 6 weeks of the procedure;
  • Patient is a woman of reproductive potential.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01113892

  Hide Study Locations
United States, Alabama
University of Alabama-Birmingham Medical Center
Birmingham, Alabama, United States, 35294
United States, Arkansas
Central Arkansas Veterans Health System
Little Rock, Arkansas, United States, 72205
United States, California
VA Palo Alto HCS
Palo Alto, California, United States, 94304
United States, Florida
University of South Florida Med Ctr
Tampa, Florida, United States, 33606
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
United States, New Hampshire
Dartmouth- Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
United States, New York
Albany Medical Center
Albany, New York, United States, 12208
Montefiore Weiler Hospital
Bronx, New York, United States, 10461
Montefiore Medical Center
Bronx, New York, United States, 10467
NYU School of Medicine
New York, New York, United States, 10016
NY Presbyterian Hosp - Columbia Univ Med Ctr
New York, New York, United States, 10032
Cornell - NY Presbyterian
New York, New York, United States, 10065
United States, Texas
Dallas VA Medical Center
Dallas, Texas, United States, 75216
Methodist Hospital
Houston, Texas, United States, 77030
Central Texas Veterans Health System
Temple, Texas, United States, 76504
Scott & White
Temple, Texas, United States, 76508
United States, Virginia
Norfolk Sentara - Norfolk General Hospital
Norfolk, Virginia, United States, 23507
United States, Washington
Swedish Medical Center
Seattle, Washington, United States, 98122
Gefasschirurgisches Zentrum Wien, Wilhelminenspital
Vienna, Austria, A-1160
Czech Republic
Fakulti Nemocnice Brno
Brno, Czech Republic, 625 00
Fakultni Nemocnice u sv Anny v Brno
Brno, Czech Republic, 656 91
University Hospital Plzen
Plzen, Czech Republic, 304 60
Vseobecna Fakultni Nemocnice (VFN)
Prague, Czech Republic, 128 08
IKEM Praha
Prague, Czech Republic, 140 21
Nemocnice Na Homolce
Prague, Czech Republic, 150 30
Klinikum Karlsruhe
Karlsruhe, Germany, 76133
Klinikum rechts der Isar Abteilung fur Gefasschirurgie
Munich, Germany, 81675
Sponsors and Collaborators
Maquet Cardiovascular
Principal Investigator: Alan Lumsden, MD The Methodist Hospital System
Principal Investigator: Nicholas J. Morrissey, MD NY Presbyterian-Columbia U Medical Center

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Maquet Cardiovascular Identifier: NCT01113892     History of Changes
Other Study ID Numbers: MCV00001506
First Posted: April 30, 2010    Key Record Dates
Last Update Posted: January 16, 2014
Last Verified: January 2014

Additional relevant MeSH terms:
Arterial Occlusive Diseases
Peripheral Arterial Disease
Vascular Diseases
Cardiovascular Diseases
Peripheral Vascular Diseases